Novartis, CH0012005267

Barclays cuts target for Novartis stock to CHF 125

Published on 10/26/2026 at 09:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays cuts its target from CHF 130 to CHF 125. Novartis stock costs EUR 137.99 on October 26, 2026, 0.57 percent below Xetra close.

Analyst view before results

Barclays cut its Novartis target from CHF 130 to CHF 125 on October 26, 2026.
Second-quarter 2026 revenue reached USD 15.0 billion, flat year over year.
Novartis stock trades at EUR 137.99 at 9:37 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.57 percent below the Xetra close of October 23, 2026 (EUR 138.78).

Draufsicht auf Tabletten, Blisterpacks, Beipackzettel und Stethoskop auf weißem Untergrund — Novartis AG CH0012005267 – Flatlay mit generischen Tabletten, Blister, Beipackzettel und Stethoskop auf Weiß, Illustration mit AI erstellt.

Novartis (CH0012005267) stock was trading at EUR 137.99 at Lang & Schwarz on October 26, 2026, down 0.57 percent from the Xetra close of October 23, 2026 (EUR 138.78). MarketScreener reported that Barclays cut its price target from CHF 130 to CHF 125 while keeping a Neutral rating on October 26, 2026.

Barclays trims the target

The analyst move places a more cautious valuation marker ahead of Novartis' third-quarter results. The company generated USD 15.0 billion of revenue in the second quarter of 2026, flat from the same quarter a year earlier, while net income fell 19 percent to USD 3.26 billion, according to Simply Wall St.

What does the target cut mean?

The immediate comparison is with the CHF 125 target, not with the euro quotation. Novartis' next earnings release is scheduled for October 27, 2026, giving investors a near-term test of revenue, earnings and full-year guidance.

Three dated developments

On October 8, 2026, Novartis received FDA approval for Rhapsido, with complete response rates of 29.3 percent versus 14.0 percent for placebo in the cited Phase III data, according to Novartis. On October 21, 2026, the European Commission approved Cosentyx for polymyalgia rheumatica, adding a 150 milligram and 300 milligram dosing framework. On October 26, 2026, Barclays reduced its target from CHF 130 to CHF 125, according to MarketScreener.

The next two dates

Novartis is due to publish third-quarter 2026 results on October 27, 2026, with the investor presentation scheduled for 1:00 p.m. CET, according to Novartis. The fiscal year 2026 results are scheduled for February 3, 2027, according to Simply Wall St.

Stock trades below Xetra close

The euro quotation was EUR 0.79 below the Xetra close as the market weighed the lower Barclays target against the approaching results. The primary listing is on SIX, where Novartis trades under the ticker NOVN.

Novartis stock was trading at EUR 137.99 at Lang & Schwarz on October 26, 2026 at 9:37 a.m. CEST, 0.57 percent below the Xetra close of October 23, 2026 (EUR 138.78). The further course of trading is shown by the continuously updated real-time quote of Novartis stock.